leuprorelin (CKD-841) / Chong Kun Dang - LARVOL DELTA

Aspire expands oncology portfolio with prostate cancer hormone therapy (Pharmabiz) - "Aspire Pharma Limited has solidified its position as a leading specialty generics enterprise by adding leuprorelin acetate as a branded generic to its oncology portfolio....Backed by £16 million of government funding, the £42 million TRANSFORM trial is set to become the largest prostate cancer diagnosis trial in two decades, involving hundreds of thousands of men. Recruitment for the trial is expected to commence in Autumn 2024."

Commercial • New trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

The Safety and Pharmacokinetic/Pharmacodynamic Study of CKD-841 in Postmenopausal Female, Phase 1 (clinicaltrials.gov) - P1; N=32; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial